Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIGHT: Pegunigalsidase alfa Switchover in Fabry Disease
NCT03180840Phase 3Completed
- Sponsor
- Protalix BioTherapeutics
- Start
- Jul 2017
- Primary completion
- Aug 2020
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 7
01
Overview
A Phase 3 trial of pegunigalsidase alfa in Fabry disease (FD), sponsored by Protalix BioTherapeutics. Started Jul 2017; status: completed.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT03180840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03180840.